Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).

Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulias V.

Am J Clin Oncol. 2002 Dec;25(6):627-31.

PMID:
12478014
2.
3.

Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.

Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulias V; Greek Colorectal Cooperative Oncology Group.

Am J Clin Oncol. 2002 Feb;25(1):65-70.

PMID:
11823700
4.
5.

Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.

Calvo E, Cortés J, Rodríguez J, Fernández-Hidalgo O, Rebollo J, Martín-Algarra S, García-Foncillas J, Martínez-Monge R, de Irala J, Brugarolas A.

Clin Colorectal Cancer. 2002 Aug;2(2):104-10.

PMID:
12453325
6.

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V.

J Clin Oncol. 2002 Jun 1;20(11):2651-7.

PMID:
12039926
7.

Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.

Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulias V.

Oncology. 2001;61(1):36-41.

PMID:
11474246
8.
9.

Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kourousis C, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V.

Dig Dis. 2007;25(1):100-5. Retraction in: Dig Dis. 2008;26(2):188.

10.

Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

Calvo E, Cortés J, González-Cao M, Rodríguez J, Aramendía JM, Fernández-Hidalgo O, Martín-Algarra S, Salgado JE, Martínez-Monge R, de Irala J, Brugarolas A.

Oncology. 2002;63(3):254-65.

PMID:
12381905
11.

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A.

Ann Oncol. 2004 Dec;15(12):1766-72.

PMID:
15550581
12.

Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.

Gholam D, Giacchetti S, Brézault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghémard O, Kustlinger F, Jasmin C, Lévi F.

Oncologist. 2006 Nov-Dec;11(10):1072-80.

13.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M.

Ann Oncol. 2000 Nov;11(11):1477-83.

PMID:
11142489
15.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest.

J Clin Oncol. 2007 May 1;25(13):1670-6.

PMID:
17470860
16.

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Cartenì G, Leo SS, Catalano G, De Lena M, Comella G.

Ann Oncol. 2000 Oct;11(10):1323-33.

PMID:
11106123
17.

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.

Comella P, Casaretti R, De Rosa V, Avallone A, Izzo F, Fiore F, Lapenta L, Comella G.

Ann Oncol. 2002 Dec;13(12):1874-81.

PMID:
12453855
18.

FDA drug approval summaries: oxaliplatin.

Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R.

Oncologist. 2004;9(1):8-12.

19.
20.

Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.

Comella P, Casaretti R, De Vita F, Avallone A, Orditura M, Petrillo A, Gravina A, Faranda A, Comis S, Comella G, Catalano G.

Ann Oncol. 1999 Aug;10(8):915-21.

PMID:
10509152

Supplemental Content

Support Center